Spero Therapeutics, Inc. (SPRO) earnings
SPRO earnings moved a median of -2.60% by the close. Quarterly and annual SPRO reports and results, each read against the price at its own news timestamp. Back to the SPRO overview →
28 measured SPRO earnings events.
Where these SPRO earnings landedvs 28 measured SPRO earnings reactions
| Middle 50% of SPRO earnings reactions | -5.98% to +0.77% |
|---|---|
| Median reaction (to close) | -2.60% |
| Measured reactions | 28 |
Point-in-time · zero look-ahead
Half of the 28 SPRO earnings events with a measured close landed between -5.98% and +0.77%; 32% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Spero Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.40% | -1.59% | |
| Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update | Press release | -0.40% | -1.59% | |
| Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 | Press release | -0.40% | +0.80% | |
| Form 10-Q Spero Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.82% | +13.12% | |
| Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update | Press release | -0.82% | +13.12% | |
| Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 | Press release | -1.22% | +2.43% | |
| Form 10-K Spero Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.63% | +2.19% | |
| Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 | Press release | +2.11% | +3.40% | |
| Form 10-Q Spero Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -6.14% | -10.00% | |
| Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | Press release | -6.14% | -10.00% | |
| Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 | Press release | +1.40% | +5.12% | |
| Form 10-Q Spero Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -7.13% | |
| Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update | Press release | +0.00% | -7.13% | |
| Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 | Press release | +1.16% | -4.69% | |
| Form 10-K Spero Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.18% | -9.82% | |
| Form 10-Q Spero Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.97% | -5.60% | |
| Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update | Press release | -0.97% | -5.60% | |
| Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 | Press release | -0.86% | +0.76% | |
| Form 10-Q Spero Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.62% | -7.97% | |
| Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update | Press release | -3.62% | -7.97% | |
| Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024 | Press release | +0.00% | -1.40% | |
| Form 10-Q Spero Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.31% | -1.88% | |
| Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update | Press release | +0.31% | -1.88% | |
| Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024 | Press release | +0.60% | +0.60% | |
| Form 10-K Spero Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.54% | -4.92% | |
| Form 10-Q Spero Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +3.07% | -4.39% | |
| Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update | Press release | +3.07% | -4.39% | |
| Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 | Press release | -0.03% | -3.33% |
Keep exploring
More SPRO: analyst actions → · SEC filings → · SPRO overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PAVmed Inc. (PAVM) | 193 | -0.49% | 41% |
| SIENNA BIOPHARMACEUTICALS (SNNA) | 193 | 0.00% | 40% |
| Xtant Medical Holdings, Inc. (XTNT) | 193 | 0.00% | 42% |
| Apollo Medical Holdings, Inc. (AMEH) | 192 | +0.16% | 55% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.